Bao Jun-Li, Han Yu-Bo, Zhang Ke, Liu Li
Heilongjiang University of Chinese Medicine, No.24, Heping Road, Xiangfang District, Haerbin.
Fist Affiliated Hospital, Heilongjiang University of Chinese Medicine, Haerbin, Heilongjiang, China.
Medicine (Baltimore). 2021 Jan 22;100(3):e23958. doi: 10.1097/MD.0000000000023958.
Pediatric obstructive sleep apnea syndrome (OSAS) is significant public concern. Clinical practice indicates that montelukast has certain therapeutic advantages, while there is a lack of evidence-based medicine support. The aim of this study is to synthesize related data to explore efficacy and safety of montelukast for pediatric OSAS.
Data in Pubmed, EMBASE, CENTRAL, CBM, CNKI, WanFang, VIP databases were comprehensively searched. All the randomized controlled trials (RCTs) in OSAS children were identified, in which the effects of montelukast on a range of outcomes were compared. The search had a deadline of January 1, 2020. Two investigators independently conducted data extraction and assessed the literature quality of the included studies. The Revman5.3 software was used for meta-analysis of the included literature.
The efficacy and safety of montelukast in the treatment of pediatric OSAS were evaluated in terms of apnea hypopnea index (AHI), the Pittsburgh Sleep Quality Index, the Epworth Sleep Scale (ESS), neck circumference, important index in Polysomnography: sleep efficiency, desaturation index, total sleep time.
This study provides reliable evidence-based support for the clinical application of montelukast in the treatment of pediatric OSAS.
CRD42020146940.
儿童阻塞性睡眠呼吸暂停综合征（OSAS）备受公众关注。临床实践表明孟鲁司特具有一定治疗优势，但缺乏循证医学支持。本研究旨在综合相关数据，探讨孟鲁司特治疗儿童OSAS的疗效和安全性。
全面检索Pubmed、EMBASE、CENTRAL、CBM、CNKI、万方、维普数据库中的数据。识别所有关于OSAS儿童的随机对照试验（RCT），比较孟鲁司特对一系列结局的影响。检索截止日期为2020年1月1日。两名研究者独立进行数据提取并评估纳入研究的文献质量。使用Revman5.3软件对纳入文献进行荟萃分析。
从呼吸暂停低通气指数（AHI）、匹兹堡睡眠质量指数、爱泼华嗜睡量表（ESS）、颈围、多导睡眠图重要指标：睡眠效率、血氧饱和度下降指数、总睡眠时间等方面评估孟鲁司特治疗儿童OSAS的疗效和安全性。
本研究为孟鲁司特治疗儿童OSAS的临床应用提供了可靠的循证支持。
CRD42020146940。
